Abstract
Uveal Melanoma (UM) is a rare tumour, with an estimated annual global incidence between 5.3-10.9 cases per million people. It accounts for less than 5% of all melanoma cases. UM arises from the vascular layers of the eye (iris, ciliary body, and choroid). It is a highly aggressive malignancy and about 50% of patients will develop metastatic disease at some stage after prior diagnosis of primary uveal melanoma. Liver is the dominant site of metastases (60-90%) followed by lungs (25%).
Highlights
Uveal Melanoma (UM) is a rare tumour, with an estimated annual global incidence between 5.3-10.9 cases per million people [1]
Data were extracted on ipilimumab dose, sample size, Objective Response Rate (ORR), Progression Free Survival (PFS), median Overall Survival, Disease Control Rate (DCR), 1 year Overall Survival (1yrOS) and 2 year Overall Survival (2yrOS)
Nine studies were included in this study including Phase II clinical trials (n = 2), Expanded Access Programs (EAP) (n = 4) and retrospective studies (n = 3)
Summary
Uveal Melanoma (UM) is a rare tumour, with an estimated annual global incidence between 5.3-10.9 cases per million people [1]. It accounts for less than 5% of all melanoma cases [2]. UM arises from the vascular layers of the eye (iris, ciliary body, and choroid). It is a highly aggressive malignancy and about 50% of patients will develop metastatic disease at some stage after prior diagnosis of primary uveal melanoma [3]. It is generally resistant to systemic therapy and there is no current standard effective therapy to treat patients with advanced disease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
